Invitae Personalized Cancer Monitoring™ - Monitoring Test
Use
The Invitae Personalized Cancer Monitoring – Monitoring Test is designed to detect minimal residual disease (MRD) and monitor anti-cancer treatment effects in a non-invasive manner. It provides prognostic information for better patient management by detecting mutations specific to the patient's tumor in circulating tumor DNA (ctDNA).
Special Instructions
Ordering this test requires a previously ordered Invitae Personalized Cancer Monitoring – Baseline Test. Not for use in pregnant patients or those with active hematological malignancy, history of allogeneic bone marrow/stem cell transplants, or recent blood transfusion. Available in the US, Canada, and Singapore.
Limitations
This test is not appropriate for identifying heritable germline mutations. A negative result does not eliminate the presence of disease. There is a potential for false negatives, especially if tumor-specific circulating material is low. Potential for sample swap errors exists despite measures to minimize them. The methodology may not detect changes in the genomic signature of relapsed or residual disease.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10mL
Minimum Volume
Not provided
Container
Streck Cell-Free DNA blood collection tubes
Collection Instructions
Collect two full tubes at the appropriate time point.
Patient Preparation
Not applicable for pregnant patients, those with active hematological malignancy, or recent blood transfusion.